New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 22, 2014
08:11 EDTMYOSMYOS reports positive top-line clinical study results for Fortetropin
MYOS announced positive top-line results of its clinical trial designed to study the effects of Fortetropin in conjunction with modest resistance training in male subjects. The University of Tampa clinical trial was designed to analyze important body composition measurements and strength performance at two dose levels of Fortetropin over a twelve week period. The randomized, double-blind, placebo controlled trial clinically demonstrated that Fortetropin resulted in statistically significant increases in both muscle size and lean body mass in average males. The study evaluated 45 male subjects adhering to a supervised nutritional intake program and a monitored modest resistance training regimen over a period of twelve weeks. The various endpoints included skeletal muscle hypertrophy, lean body mass, fat mass and measurements of strength and power. Subjects taking Fortetropin showed significantly improved lean body mass and increased muscle size compared to placebo.
News For MYOS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 22, 2015
08:12 EDTMYOSMYOS study of Fortetropin mechanism of action shows regulatory effects
MYOS announced that its mechanism of action studies have identified three key molecular signaling pathways in which Fortetropin exhibits regulatory effects. In addition to reducing serum myostatin levels, MYOS recently completed a preclinical mechanism of action study that demonstrated Fortetropin's activity in mTOR and Ubiquitin, two other crucial signaling pathways in the growth and maintenance of healthy muscle. In addition to myostatin regulation, MYOS' preclinical data also showed that Fortetropin up-regulates the mTOR regulatory pathway. The mTOR pathway is responsible for production of a protein kinase related to cell growth and proliferation that increases skeletal muscle mass. Up-regulation of the mTOR pathway is important in preventing muscle atrophy. Fortetropin's ability to affect the mTOR pathway may have a significant impact in treating patients suffering from degenerative muscle diseases and suggests that Fortetropin-based products may help slow muscle loss secondary to immobility and denervation. Finally, the company's recent animal model study demonstrated that Fortetropin acts to reduce the synthesis of proteins in the Ubiquitin pathway, a highly selective, tightly regulated system that serves to activate muscle breakdown. Over-production in the Ubiquitin pathway is responsible for muscle degradation. Fortetropin's ability to regulate production in the Ubiquitin pathway may have significant implications for repairing age-related muscle loss and for patients suffering from chronic diseases causing cachexia.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use